Skip to main content

Effect of megadose vitamin C in patients with sepsis: the CEMVIS randomized clinical trial

In brief

Megadose vitamin C fails to lower 28-day sepsis mortality in trial

In a randomized trial of 231 adults with sepsis, 28-day mortality was nearly identical with megadose vitamin C and placebo: 30.7% versus 31.0%. Outcomes differed numerically by shock status, but the overall trial does not support routine use; vitamin C also caused more hypernatremia, and the subgroup signal needs confirmation.

Journal
Critical care (London, England) (Q1)
Published
24 August 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Jianbin Guan, Guizhong Wang, Zhihui Liang, Wei Peng, Xifan Yang, Shaowu Chen, et al.
PMID
43053147
DOI
10.1186/s13054-026-06280-7

Why clinicians should know about it

Abstract

BACKGROUND: Previous randomized trials of vitamin C in sepsis have reported conflicting findings, but whether the effect of vitamin C varies according to septic shock status remains unclear. We aimed to evaluate the effect of megadose vitamin C in sepsis and explore whether treatment effect differed according to septic shock status. METHODS: CEMVIS was a multicenter, randomized, single-blind, placebo-controlled trial conducted in four tertiary hospitals in China. Adults meeting Sepsis-3 criteria were randomly assigned (1:1) to receive intravenous vitamin C (12 g every 12 h for 4 days) or placebo using stratified randomization according to septic shock status. Patients were analyzed according to the modified intention-to-treat principle. The primary outcome was 28-day mortality. RESULTS: Between Feb 8, 2022, and Dec 25, 2024, 114 patients in the vitamin C group and 117 in the placebo group were included in the modified intention-to-treat population. 28-day mortality did not differ significantly between groups (35/114 [30.7%] vs 36/116 [31.0%]; odds ratio 0.99, 95% CI 0.56-1.74; p = 0.97). No significant differences were observed in the duration of mechanical ventilation, vasopressor therapy, and renal replacement therapy, or in changes in SOFA scores over 96 hours. Prespecified subgroup analyses showed significant interaction according to septic shock status (P for interaction = 0.026), with the treatment effects on 28-day mortality numerically favoring vitamin C among patients without septic shock (15.4% vs 34%) and numerically favoring placebo among those with septic shock (38.7% vs 29%). Hypernatremia occurred more frequently in the vitamin C group (40/114 [35.1%] vs 24/117 [20.5%]; p = 0.02). Exploratory restricted cubic spline analyses showed that increasing lactate levels were associated with a progressive shift in treatment effect from potential benefit toward potential harm. Post hoc Bayesian analyses further provided probabilistic characterization of the potential treatment effect according to septic shock status. CONCLUSIONS: The results of this trial do not support the routine use of megadose vitamin C to reduce 28-day mortality in patients with sepsis. Treatment effects may vary according to septic shock status. TRIAL REGISTRATION: This trial was registered with ClinicalTrials.gov on 3 January 2022 (identifier: NCT05194189).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.